Trial Profile
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Add-on Study of MLR 1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tolimidone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Melior Pharmaceuticals, Inc.
- 06 Jan 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Jan 2019).
- 14 May 2019 Results published in the Media Release
- 16 Oct 2018 Status changed from recruiting to active, no longer recruiting, according to a Melior Pharmaceuticals, Inc.media release.